48.00
+4.45(+10.22%)
Currency In USD
| Previous Close | 43.55 |
| Open | 43.5 |
| Day High | 49.98 |
| Day Low | 41.83 |
| 52-Week High | 49.98 |
| 52-Week Low | 1.55 |
| Volume | 80,302 |
| Average Volume | 90,300 |
| Market Cap | 292.92M |
| PE | -24.49 |
| EPS | -1.96 |
| Moving Average 50 Days | 26.81 |
| Moving Average 200 Days | 10.7 |
| Change | 4.45 |
If you invested $1000 in Monopar Therapeutics Inc. (MNPR) since IPO date, it would be worth $362.26 as of February 05, 2025 at a share price of $48. Whereas If you bought $1000 worth of Monopar Therapeutics Inc. (MNPR) shares 5 years ago, it would be worth $633.25 as of February 05, 2025 at a share price of $48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
GlobeNewswire Inc.
Dec 20, 2024 2:00 PM GMT
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
GlobeNewswire Inc.
Dec 05, 2024 9:21 PM GMT
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Dec 03, 2024 1:00 PM GMT
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robi